Our findings demonstrate, for the first time, that five newly synthesized vemurafenib analogs—RF-86A, RF-87A, RF-94A, RF-94B, and RF-96B—effectively reduce the viability of A375 human melanoma cells and inhibit metastatic potential through suppression of MMP-2 and MMP-9 activity. Here, MMP9 is linked to melanoma.